|Ancriviroc (SCH351125) is an orally available, small molecule antagonist of the C-C chemokine receptor type 5 (CCR5) expressed on T cells . The compound was originally investigated as an anti-HIV therapeutic . SCH351125-induced CCR5 blockade was investigated for action in treating rheumatoid arthritis, but with discouraging clinical trial results . Other CCR5 antagonists (AZD5672 and maraviroc) have also proven ineffective in RA clinical trials .
There is some ambiguity in the literature and online databases as to the exact structure of ancriviroc. The structure shown here matches that in the PubChem entry linked to above, and as shown in , while other common representations of ancriviroc match CID 5479787.